Perceptions of Painful Diabetic Peripheral Neuropathy in South-East Asia

Results from Patient and Physician Surveys

Rayaz Malik, Emre Aldinc, Siew Pheng Chan, Chaicharn Deerochanawong, Chii Min Hwu, Raymond L. Rosales, Chun Yip Yeung, Koichi Fujii, Bruce Parsons

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Abstract: There are no data on physician–patient communication in painful diabetic peripheral neuropathy (pDPN) in the Asia–Pacific region. The objective of this study was to examine patient and physician perceptions of pDPN and clinical practice behaviors in five countries in South-East Asia. Primary care physicians and practitioners, endocrinologists, diabetologists, and patients with pDPN completed separate surveys on pDPN diagnosis, impact, management, and physician–patient interactions in Hong Kong, Malaysia, the Philippines, Taiwan, and Thailand. Data were obtained from 100 physicians and 100 patients in each country. The majority of physicians (range across countries, 30–85%) were primary care physicians and practitioners. Patients were mostly aged 18–55 years and had been diagnosed with diabetes for >5 years. Physicians believed pDPN had a greater impact on quality of life than did patients (ranges 83–92% and 39–72%, respectively), but patients believed pDPN had a greater impact on items such as sleep, anxiety, depression, and work than physicians. Physicians considered the diagnosis and treatment of pDPN a low priority, which may be reflected in the generally low incidence of screening (range 12–65%) and a lack of awareness of pDPN. Barriers to treatment included patients’ lack of awareness of pDPN. Both physicians and patients agreed that pain scales and local language descriptions were the most useful tools in helping to describe patients’ pain. Most patients were monitored upon diagnosis of pDPN (range 55–97%), but patients reported a shorter duration of monitoring compared with physicians. Both physicians and patients agreed that it was patients who initiated conversations on pDPN. Physicians most commonly referred to guidelines from the American Diabetes Association or local guidelines for the management of pDPN. This study highlights important differences between physician and patient perceptions of pDPN, which may impact on its diagnosis and treatment. For a chronic and debilitating complication like pDPN, the physician–patient dialogue is central to maximizing patient outcomes. Strategies, including education of both groups, need to be developed to improve communication. Funding: Pfizer.

Original languageEnglish
Pages (from-to)1426-1437
Number of pages12
JournalAdvances in Therapy
Volume34
Issue number6
DOIs
Publication statusPublished - 1 Jun 2017

Fingerprint

Far East
Diabetic Neuropathies
Peripheral Nervous System Diseases
Physicians
Surveys and Questionnaires
Primary Care Physicians
Communication
Guidelines
Pain
Philippines
Malaysia
Hong Kong
Thailand
Taiwan

Keywords

  • Chronic pain
  • Diabetes
  • Diagnosis
  • Impact
  • Painful diabetic peripheral neuropathy
  • Patient–physician dialogue

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Perceptions of Painful Diabetic Peripheral Neuropathy in South-East Asia : Results from Patient and Physician Surveys. / Malik, Rayaz; Aldinc, Emre; Chan, Siew Pheng; Deerochanawong, Chaicharn; Hwu, Chii Min; Rosales, Raymond L.; Yeung, Chun Yip; Fujii, Koichi; Parsons, Bruce.

In: Advances in Therapy, Vol. 34, No. 6, 01.06.2017, p. 1426-1437.

Research output: Contribution to journalArticle

Malik, R, Aldinc, E, Chan, SP, Deerochanawong, C, Hwu, CM, Rosales, RL, Yeung, CY, Fujii, K & Parsons, B 2017, 'Perceptions of Painful Diabetic Peripheral Neuropathy in South-East Asia: Results from Patient and Physician Surveys', Advances in Therapy, vol. 34, no. 6, pp. 1426-1437. https://doi.org/10.1007/s12325-017-0536-5
Malik, Rayaz ; Aldinc, Emre ; Chan, Siew Pheng ; Deerochanawong, Chaicharn ; Hwu, Chii Min ; Rosales, Raymond L. ; Yeung, Chun Yip ; Fujii, Koichi ; Parsons, Bruce. / Perceptions of Painful Diabetic Peripheral Neuropathy in South-East Asia : Results from Patient and Physician Surveys. In: Advances in Therapy. 2017 ; Vol. 34, No. 6. pp. 1426-1437.
@article{f0d03ed137c3437d8bccfa21f095e44b,
title = "Perceptions of Painful Diabetic Peripheral Neuropathy in South-East Asia: Results from Patient and Physician Surveys",
abstract = "Abstract: There are no data on physician–patient communication in painful diabetic peripheral neuropathy (pDPN) in the Asia–Pacific region. The objective of this study was to examine patient and physician perceptions of pDPN and clinical practice behaviors in five countries in South-East Asia. Primary care physicians and practitioners, endocrinologists, diabetologists, and patients with pDPN completed separate surveys on pDPN diagnosis, impact, management, and physician–patient interactions in Hong Kong, Malaysia, the Philippines, Taiwan, and Thailand. Data were obtained from 100 physicians and 100 patients in each country. The majority of physicians (range across countries, 30–85{\%}) were primary care physicians and practitioners. Patients were mostly aged 18–55 years and had been diagnosed with diabetes for >5 years. Physicians believed pDPN had a greater impact on quality of life than did patients (ranges 83–92{\%} and 39–72{\%}, respectively), but patients believed pDPN had a greater impact on items such as sleep, anxiety, depression, and work than physicians. Physicians considered the diagnosis and treatment of pDPN a low priority, which may be reflected in the generally low incidence of screening (range 12–65{\%}) and a lack of awareness of pDPN. Barriers to treatment included patients’ lack of awareness of pDPN. Both physicians and patients agreed that pain scales and local language descriptions were the most useful tools in helping to describe patients’ pain. Most patients were monitored upon diagnosis of pDPN (range 55–97{\%}), but patients reported a shorter duration of monitoring compared with physicians. Both physicians and patients agreed that it was patients who initiated conversations on pDPN. Physicians most commonly referred to guidelines from the American Diabetes Association or local guidelines for the management of pDPN. This study highlights important differences between physician and patient perceptions of pDPN, which may impact on its diagnosis and treatment. For a chronic and debilitating complication like pDPN, the physician–patient dialogue is central to maximizing patient outcomes. Strategies, including education of both groups, need to be developed to improve communication. Funding: Pfizer.",
keywords = "Chronic pain, Diabetes, Diagnosis, Impact, Painful diabetic peripheral neuropathy, Patient–physician dialogue",
author = "Rayaz Malik and Emre Aldinc and Chan, {Siew Pheng} and Chaicharn Deerochanawong and Hwu, {Chii Min} and Rosales, {Raymond L.} and Yeung, {Chun Yip} and Koichi Fujii and Bruce Parsons",
year = "2017",
month = "6",
day = "1",
doi = "10.1007/s12325-017-0536-5",
language = "English",
volume = "34",
pages = "1426--1437",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "6",

}

TY - JOUR

T1 - Perceptions of Painful Diabetic Peripheral Neuropathy in South-East Asia

T2 - Results from Patient and Physician Surveys

AU - Malik, Rayaz

AU - Aldinc, Emre

AU - Chan, Siew Pheng

AU - Deerochanawong, Chaicharn

AU - Hwu, Chii Min

AU - Rosales, Raymond L.

AU - Yeung, Chun Yip

AU - Fujii, Koichi

AU - Parsons, Bruce

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Abstract: There are no data on physician–patient communication in painful diabetic peripheral neuropathy (pDPN) in the Asia–Pacific region. The objective of this study was to examine patient and physician perceptions of pDPN and clinical practice behaviors in five countries in South-East Asia. Primary care physicians and practitioners, endocrinologists, diabetologists, and patients with pDPN completed separate surveys on pDPN diagnosis, impact, management, and physician–patient interactions in Hong Kong, Malaysia, the Philippines, Taiwan, and Thailand. Data were obtained from 100 physicians and 100 patients in each country. The majority of physicians (range across countries, 30–85%) were primary care physicians and practitioners. Patients were mostly aged 18–55 years and had been diagnosed with diabetes for >5 years. Physicians believed pDPN had a greater impact on quality of life than did patients (ranges 83–92% and 39–72%, respectively), but patients believed pDPN had a greater impact on items such as sleep, anxiety, depression, and work than physicians. Physicians considered the diagnosis and treatment of pDPN a low priority, which may be reflected in the generally low incidence of screening (range 12–65%) and a lack of awareness of pDPN. Barriers to treatment included patients’ lack of awareness of pDPN. Both physicians and patients agreed that pain scales and local language descriptions were the most useful tools in helping to describe patients’ pain. Most patients were monitored upon diagnosis of pDPN (range 55–97%), but patients reported a shorter duration of monitoring compared with physicians. Both physicians and patients agreed that it was patients who initiated conversations on pDPN. Physicians most commonly referred to guidelines from the American Diabetes Association or local guidelines for the management of pDPN. This study highlights important differences between physician and patient perceptions of pDPN, which may impact on its diagnosis and treatment. For a chronic and debilitating complication like pDPN, the physician–patient dialogue is central to maximizing patient outcomes. Strategies, including education of both groups, need to be developed to improve communication. Funding: Pfizer.

AB - Abstract: There are no data on physician–patient communication in painful diabetic peripheral neuropathy (pDPN) in the Asia–Pacific region. The objective of this study was to examine patient and physician perceptions of pDPN and clinical practice behaviors in five countries in South-East Asia. Primary care physicians and practitioners, endocrinologists, diabetologists, and patients with pDPN completed separate surveys on pDPN diagnosis, impact, management, and physician–patient interactions in Hong Kong, Malaysia, the Philippines, Taiwan, and Thailand. Data were obtained from 100 physicians and 100 patients in each country. The majority of physicians (range across countries, 30–85%) were primary care physicians and practitioners. Patients were mostly aged 18–55 years and had been diagnosed with diabetes for >5 years. Physicians believed pDPN had a greater impact on quality of life than did patients (ranges 83–92% and 39–72%, respectively), but patients believed pDPN had a greater impact on items such as sleep, anxiety, depression, and work than physicians. Physicians considered the diagnosis and treatment of pDPN a low priority, which may be reflected in the generally low incidence of screening (range 12–65%) and a lack of awareness of pDPN. Barriers to treatment included patients’ lack of awareness of pDPN. Both physicians and patients agreed that pain scales and local language descriptions were the most useful tools in helping to describe patients’ pain. Most patients were monitored upon diagnosis of pDPN (range 55–97%), but patients reported a shorter duration of monitoring compared with physicians. Both physicians and patients agreed that it was patients who initiated conversations on pDPN. Physicians most commonly referred to guidelines from the American Diabetes Association or local guidelines for the management of pDPN. This study highlights important differences between physician and patient perceptions of pDPN, which may impact on its diagnosis and treatment. For a chronic and debilitating complication like pDPN, the physician–patient dialogue is central to maximizing patient outcomes. Strategies, including education of both groups, need to be developed to improve communication. Funding: Pfizer.

KW - Chronic pain

KW - Diabetes

KW - Diagnosis

KW - Impact

KW - Painful diabetic peripheral neuropathy

KW - Patient–physician dialogue

UR - http://www.scopus.com/inward/record.url?scp=85019187907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019187907&partnerID=8YFLogxK

U2 - 10.1007/s12325-017-0536-5

DO - 10.1007/s12325-017-0536-5

M3 - Article

VL - 34

SP - 1426

EP - 1437

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 6

ER -